This article is more than 5 years old. Information may no longer be current.

VIDEO: Novel agent improves response rate in urothelial cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO – A novel antibody drug conjugate demonstrated promising activity among patients with metastatic urothelial cancer, according to a study presented at the ASCO Annual Meeting.

Elizabeth Plimack, MD, MS, chief of the division of genitourinary medical oncology and director of genitourinary clinical research at Fox Chase Cancer Center, reviews the findings of the trial as well as future directions for the agent.

The response rate observed was “higher than the typical response rate we see with single-agent immunotherapy … and certainly higher than what we’ve seen historically with chemotherapy,” Plimack told HemOnc Today.